|Bid||0.23 x 10000|
|Ask||0.29 x 10000|
|Day's Range||36.01 - 36.01|
|52 Week Range||15.00 - 36.75|
|Beta (5Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.00|
Capstone Subsidiary Issues Debt to Acquire Equity Interest in Operating CompanyALSIP, IL / ACCESSWIRE / April 6, 2021 / On March 31, 2021, the Company, through its relationship with Brookstone Partners (New York), executed definitive documents and acquired a minority interest in a consumer products company, Diamond Products, LLC ("Diamond"), a sexual wellness holding company.0 million, which bears interest at 1% per annum and has a 3-year term, and secured its obligations thereunder by pledging Beta's interests in DPH; and\--As additional credit support, the Company issued a limited payment guaranty to Brookstone XXI in the amount of 10% of the principal amount of Beta's promissory note.
ALSIP, IL / ACCESSWIRE / March 31, 2021 / Capstone Therapeutics (OTCQB:CAPS) ("the Company") today filed its Annual Report for the year ended December 31, 2020 with the OTCQB at www. Net income attributable to Capstone Therapeutics Corp.
ALSIP, IL / ACCESSWIRE / February 18, 2021/Capstone Therapeutics (OTCQB:CAPS) ("the Company") On February 5, 2021, the Company held a special shareholder meeting following notice and distribution of a proxy statement setting forth four proposals for shareholder vote. The meeting was held virtually by video conference due to Covid restrictions with the members of the Company's Board of Directors and a Computershare representative, serving as Inspector of the Election, present.